Should Neoadjuvant Treatment Be Adopted More Widely for Patients With Extremity Soft Tissue Sarcoma in Low-Income Countries?
JCO Global Oncology · 2023
DOI: 10.1200/go.23.00110 ↗Kurz gefasst
Leserbrief in der Zeitschrift JCO Global Oncology, 2023. Verfasst von Ankit Mangla. Beteiligte Einrichtung: Ankit Mangla, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, Case Western Reserve University School of Medicine, Cleveland, OH, Case …. Hauptthemen laut MEDLINE: Sarcoma, Soft Tissue Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The article by Raza et al 1 regarding the management of localized extremity soft tissue sarcoma (ESTS) in a tertiary care center in Pakistan is a valuable insight into how these rare tumors are treated in low-income countries.Surgical resection with perioperative radiation therapy (RT) is the standard of care for patients presenting with localized ESTS. 2 The use of neoadjuvant or adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (STS) is an ongoing debate.However, nomograms from the Sloan-Kettering center and SARCULATOR have been validated in retrospective cohorts to help identify patients who may benefit from neoadjuvant chemotherapy.3 The authors report 72% of patients had positive margins after surgical resection (it is unclear if this was microscopic or macroscopic positive margin).In addition, the overall survival (OS) and disease-free survival (DFS) at 2 years are 50% and 63%, respectively, with a median DFS of 8 months.Although they cite the advanced stage as a reason for such numbers, perhaps adopting neoadjuvant therapies (both radiation and chemotherapy) for such patients may help truncate these numbers, even in patients who present with stage T2 and above ESTS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Ankit Mangla, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, Case Western Reserve University School of Medicine, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH.
ORCID-Profile: Ankit Mangla
Zitieren
APA
Mangla, A. (2023). Should Neoadjuvant Treatment Be Adopted More Widely for Patients With Extremity Soft Tissue Sarcoma in Low-Income Countries?. JCO Global Oncology. https://doi.org/10.1200/go.23.00110
Vancouver
Mangla A. Should Neoadjuvant Treatment Be Adopted More Widely for Patients With Extremity Soft Tissue Sarcoma in Low-Income Countries?. JCO Global Oncology. 2023. doi:10.1200/go.23.00110
BibTeX
@article{Mangla2023,
author = {Mangla, Ankit},
title = {Should Neoadjuvant Treatment Be Adopted More Widely for Patients With Extremity Soft Tissue Sarcoma in Low-Income Countries?},
journal = {JCO Global Oncology},
year = {2023},
doi = {10.1200/go.23.00110}
}
EUVIMED